Genmab A/S (GMAB) Stock Insights

GMAB price $57.29 +12.62 +28.25%

Ticker
GMAB
Price
$57.29
Change
+12.62 +28.25%
Market cap ?
$35.23B
P/E ?
40.62
Forward P/E ?
48.55
Dividend yield ?
0.00%
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
37
Value
29
Quality
63
Growth
20

Stocklytics score rationale: value 29, quality 63, growth 20.

Financials

2016201720182019202020212022202320242025
18161220002365436000302513700053660000001011100000084170000001450500000016474000000215260000003722933872

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and…

Fair value

GMAB fair value $81.67. Price $57.29. Price is 30% below fair value.

Below fair value, but more expensive than usual. A smaller discount than on more than 99% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Average free cash flow, last three years 5.25B. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 614.90M. Net debt 3.71B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare GMAB

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—0.37—1.20B
2026-08-060.540.371.16B1.12B
2026-05-070.090.15896.00M905.77M
2026-02-170.050.461.06B1.07B
2025-11-060.650.481.02B1.01B
2025-08-070.540.39924.81M952.56M
2025-05-080.310.23725.99M755.47M
2025-02-120.570.36895.80M894.71M
2024-11-060.290.35815.16M809.62M
2024-08-080.220.29789.59M732.47M
2024-05-020.160.16598.08M572.03M
2024-02-140.360.34675.34M671.21M
2023-11-070.473.14669.38M642.86M
2023-08-030.302.18613.29M601.13M
2023-05-100.050.65416.08M404.26M
2023-02-220.123.15754.97M681.42M
2022-11-090.531.65535.64M473.49M
2022-08-100.411.55443.98M412.04M
2022-05-110.110.91315.14M300.49M
2022-02-160.175.30399.16M389.00M
2021-11-100.210.11360.41M270.35M
2021-08-110.080.08314.36M353.27M
2021-05-050.270.23249.78M214.32M
2021-02-230.141.28335.62M563.55M
2020-11-040.130.99271.70M459.63M
2020-08-120.760.88822.37M231.81M
2020-05-060.060.06129.82M763.51M
2020-02-190.340.36449.49M430.54M
2019-11-061.260.08152.42M195.69M
2019-08-200.200.27117.59M144.85M
2019-03-310.02—88.87M—
2018-12-310.22—198.32M—
2018-09-300.05—93.53M—
2018-06-300.07—79.34M—
2018-03-310.05—112.55M—
2017-12-310.20—160.31M—
2017-09-30-0.00—51.15M—
2017-06-300.08—118.46M—
2017-03-310.00—36.09M—
2016-12-310.19—130.83M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
No data yet.

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 307, holders +26 vs prior quarter. Ownership 16.70%.

HolderSharesChangeChange %Value
PARADIGM BIOCAPITAL ADVISORS LP13.13M5.17M+64.83%360.77M
ORBIS ALLAN GRAY LTD11.37M-1.56M-12.05%312.28M
ALLIANCEBERNSTEIN L.P.8.64M-912.27K-9.55%231.94M
DEERFIELD MANAGEMENT COMPANY, L.P.6.87M4.40M+178.84%188.58M
DEEP TRACK CAPITAL, LP5.65M1.99M+54.23%155.21M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP4.98M00.00%136.67M
BLACKROCK, INC.4.67M134.69K+2.97%128.32M
SOFINNOVA INVESTMENTS, INC.4.05M3.29M+437.74%111.12M
RENAISSANCE TECHNOLOGIES LLC3.52M-896.70K-20.31%96.64M
TWO SIGMA INVESTMENTS, LP3.51M1.17M+49.90%96.33M
HARDING LOEVNER LP3.09M-145.28K-4.50%86.90M
DEEP TRACK CAPITAL, LP3.00M-663.25K-18.11%82.41M
FIRST TRUST ADVISORS LP2.76M295.18K+11.99%75.72M
CITADEL ADVISORS LLC2.48M2.30M+1335.36%68.02M
QUBE RESEARCH & TECHNOLOGIES LTD1.69M1.01M+149.40%46.40M
MORGAN STANLEY1.63M-554.54K-25.38%44.78M
FEDERATED HERMES, INC.1.45M197.79K+15.80%39.81M
GOLDMAN SACHS GROUP INC1.28M347.97K+37.37%35.14M
FRANKLIN TEMPLETON INC1.20M9.78K+0.82%33.04M
PICTET ASSET MANAGEMENT HOLDING SA1.07M-11.54K-1.07%29.28M
UBS GROUP AG961.05K662.92K+222.36%26.40M
PERPETUAL LTD919.05K160.54K+21.17%25.25M
NORTHERN TRUST CORP916.60K-33.93K-3.57%25.18M
MILLENNIUM MANAGEMENT LLC910.60K118.31K+14.93%25.01M
RUSSELL INVESTMENTS GROUP, LTD.883.43K86.36K+10.83%24.27M

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Genmab A/S (GMAB) Stock Insights

GMAB$57.29+12.62 +28.25%

$35.23B

Market Cap

40.62

P/E

48.55

Forward P/E

37

Score

Price History